It Seems Juniper Pharmaceuticals, Inc. (JNP) Will Go Up. Have Another Big Increase

March 14, 2018 - By Linda Rogers

The stock of Juniper Pharmaceuticals, Inc. (NASDAQ:JNP) is a huge mover today! The stock increased 3.64% or $0.4 during the last trading session, reaching $11.4. About 146,385 shares traded or 106.71% up from the average. Juniper Pharmaceuticals, Inc. (NASDAQ:JNP) has declined 42.39% since March 14, 2017 and is downtrending. It has underperformed by 59.09% the S&P500.
The move comes after 8 months positive chart setup for the $125.12M company. It was reported on Mar, 14 by We have $12.20 PT which if reached, will make NASDAQ:JNP worth $8.76 million more.

Analysts await Juniper Pharmaceuticals, Inc. (NASDAQ:JNP) to report earnings on May, 3. They expect $0.02 EPS, up 115.38 % or $0.15 from last year’s $-0.13 per share. JNP’s profit will be $219,504 for 142.50 P/E if the $0.02 EPS becomes a reality. After $0.11 actual EPS reported by Juniper Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts -81.82 % negative EPS growth.

Juniper Pharmaceuticals, Inc. (NASDAQ:JNP) Ratings Coverage

Among 5 analysts covering Juniper Pharmaceuticals Inc (NASDAQ:JNP), 2 have Buy rating, 0 Sell and 3 Hold. Therefore 40% are positive. Juniper Pharmaceuticals Inc had 7 analyst reports since August 26, 2015 according to SRatingsIntel. H.C. Wainwright downgraded it to “Neutral” rating and $6.75 target in Friday, August 19 report. Bernstein downgraded Juniper Pharmaceuticals, Inc. (NASDAQ:JNP) on Monday, January 9 to “Market Perform” rating. The firm earned “Outperform” rating on Tuesday, January 26 by Northland Capital. Roth Capital initiated it with “Buy” rating and $12.0 target in Tuesday, January 2 report. As per Thursday, August 18, the company rating was downgraded by Northland Capital. The firm has “Buy” rating by TheStreet given on Wednesday, August 26.

More notable recent Juniper Pharmaceuticals, Inc. (NASDAQ:JNP) news were published by: which released: “Juniper Pharmaceuticals’ (JNP) CEO Alicia Secor on Q3 2017 Results – Earnings …” on November 05, 2017, also with their article: “Juniper Pharmaceuticals: A High Risk, High Reward Women’s Health Play” published on October 27, 2017, published: “Juniper Pharmaceuticals Announces 4.5-Year Extension through 2024 of CRINONE …” on January 08, 2018. More interesting news about Juniper Pharmaceuticals, Inc. (NASDAQ:JNP) were released by: and their article: “Juniper Pharmaceutical investors reject one director” published on July 05, 2017 as well as‘s news article titled: “Juniper Pharmaceuticals Announces Results of 2017 Annual Meeting” with publication date: July 05, 2017.

Juniper Pharmaceuticals, Inc., a womenÂ’s health therapeutic company, focuses on developing therapeutics that address unmet medical needs in women's health. The company has market cap of $125.12 million. The firm develops its products using its drug delivery technologies, including bioadhesive delivery system, a polymer designed to adhere to epithelial surfaces or mucosa for sustained and controlled delivery of active drug product; and a novel intra-vaginal ring technology. It currently has negative earnings. It markets CRINONE, a progesterone bioadhesive vaginal gel for progesterone supplementation or replacement as part of an assisted reproductive technology treatment for infertile women with progesterone deficiency.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: